| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Non-Hodgkin | 10 | 2015 | 261 | 2.300 |
Why?
|
| Diet | 16 | 2017 | 443 | 1.950 |
Why?
|
| Feeding Behavior | 7 | 2016 | 327 | 1.690 |
Why?
|
| Heart Defects, Congenital | 11 | 2024 | 363 | 1.620 |
Why?
|
| Acute Kidney Injury | 9 | 2024 | 313 | 1.570 |
Why?
|
| Microbiota | 8 | 2023 | 403 | 1.540 |
Why?
|
| Rheumatic Heart Disease | 7 | 2024 | 30 | 1.500 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 983 | 1.300 |
Why?
|
| Child | 45 | 2024 | 7178 | 1.110 |
Why?
|
| Infant | 25 | 2024 | 3162 | 0.960 |
Why?
|
| Mothers | 3 | 2021 | 142 | 0.950 |
Why?
|
| Vegetables | 3 | 2013 | 47 | 0.950 |
Why?
|
| Fruit | 3 | 2013 | 76 | 0.930 |
Why?
|
| Female | 87 | 2024 | 46264 | 0.930 |
Why?
|
| Postmenopause | 4 | 2013 | 102 | 0.920 |
Why?
|
| Virtual Reality | 5 | 2023 | 24 | 0.900 |
Why?
|
| Humans | 117 | 2024 | 89435 | 0.880 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2023 | 157 | 0.870 |
Why?
|
| Nutritional Status | 2 | 2014 | 80 | 0.860 |
Why?
|
| Adolescent | 38 | 2024 | 9270 | 0.860 |
Why?
|
| Cohort Studies | 23 | 2024 | 2875 | 0.840 |
Why?
|
| Male | 74 | 2024 | 42455 | 0.800 |
Why?
|
| Risk Factors | 26 | 2024 | 5499 | 0.760 |
Why?
|
| Health Behavior | 3 | 2011 | 186 | 0.740 |
Why?
|
| Retrospective Studies | 36 | 2024 | 9064 | 0.730 |
Why?
|
| Infant, Newborn | 20 | 2024 | 2488 | 0.720 |
Why?
|
| Weight Perception | 1 | 2020 | 1 | 0.720 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 26 | 0.710 |
Why?
|
| Body Image | 1 | 2020 | 78 | 0.690 |
Why?
|
| Case-Control Studies | 15 | 2021 | 1862 | 0.670 |
Why?
|
| Pediatrics | 7 | 2021 | 356 | 0.650 |
Why?
|
| Young Adult | 26 | 2024 | 6322 | 0.640 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 229 | 0.630 |
Why?
|
| Child, Preschool | 18 | 2024 | 3737 | 0.620 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2024 | 476 | 0.600 |
Why?
|
| Fontan Procedure | 3 | 2023 | 56 | 0.570 |
Why?
|
| Heart Ventricles | 5 | 2024 | 779 | 0.560 |
Why?
|
| Surveys and Questionnaires | 9 | 2020 | 2633 | 0.540 |
Why?
|
| Urine | 1 | 2016 | 89 | 0.540 |
Why?
|
| Adult | 36 | 2024 | 26646 | 0.530 |
Why?
|
| Aged | 30 | 2023 | 19185 | 0.520 |
Why?
|
| Lung Transplantation | 3 | 2024 | 292 | 0.520 |
Why?
|
| Meat Products | 2 | 2012 | 7 | 0.520 |
Why?
|
| Crohn Disease | 4 | 2024 | 762 | 0.510 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 192 | 0.510 |
Why?
|
| Soy Foods | 2 | 2011 | 3 | 0.500 |
Why?
|
| Food | 2 | 2015 | 90 | 0.500 |
Why?
|
| Prospective Studies | 18 | 2024 | 4297 | 0.490 |
Why?
|
| Calcium, Dietary | 1 | 2015 | 64 | 0.490 |
Why?
|
| Rheumatic Fever | 3 | 2024 | 12 | 0.490 |
Why?
|
| Premature Birth | 1 | 2016 | 118 | 0.480 |
Why?
|
| Lipocalin-2 | 2 | 2024 | 38 | 0.480 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2014 | 3 | 0.480 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2014 | 12 | 0.480 |
Why?
|
| Curriculum | 7 | 2023 | 568 | 0.470 |
Why?
|
| Middle Aged | 31 | 2023 | 26008 | 0.470 |
Why?
|
| Proportional Hazards Models | 11 | 2023 | 852 | 0.450 |
Why?
|
| Leptin | 2 | 2014 | 102 | 0.450 |
Why?
|
| Energy Intake | 5 | 2017 | 97 | 0.440 |
Why?
|
| Carotenoids | 2 | 2013 | 15 | 0.430 |
Why?
|
| Adiponectin | 1 | 2013 | 20 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2024 | 510 | 0.430 |
Why?
|
| Diet, Western | 1 | 2013 | 38 | 0.430 |
Why?
|
| Phytanic Acid | 1 | 2012 | 3 | 0.430 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 46 | 0.420 |
Why?
|
| Hawaii | 10 | 2016 | 25 | 0.420 |
Why?
|
| Registries | 4 | 2024 | 788 | 0.420 |
Why?
|
| Smoking | 3 | 2013 | 622 | 0.420 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 17 | 0.410 |
Why?
|
| Amines | 1 | 2012 | 28 | 0.410 |
Why?
|
| Food Supply | 1 | 2012 | 29 | 0.410 |
Why?
|
| Somatomedins | 1 | 2012 | 28 | 0.410 |
Why?
|
| Phytoestrogens | 1 | 2011 | 2 | 0.400 |
Why?
|
| Isoflavones | 1 | 2011 | 13 | 0.400 |
Why?
|
| Growth Inhibitors | 1 | 2011 | 42 | 0.400 |
Why?
|
| Heart | 4 | 2023 | 574 | 0.400 |
Why?
|
| Fabaceae | 1 | 2011 | 25 | 0.400 |
Why?
|
| Heart Transplantation | 3 | 2022 | 717 | 0.390 |
Why?
|
| Norwood Procedures | 2 | 2024 | 40 | 0.390 |
Why?
|
| Cardiac Volume | 2 | 2022 | 53 | 0.390 |
Why?
|
| Food Labeling | 1 | 2010 | 8 | 0.360 |
Why?
|
| Aortic Diseases | 2 | 2023 | 102 | 0.360 |
Why?
|
| Risk Assessment | 8 | 2024 | 2306 | 0.360 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 538 | 0.360 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 353 | 0.340 |
Why?
|
| Health Status Disparities | 2 | 2014 | 188 | 0.340 |
Why?
|
| Communication | 3 | 2018 | 458 | 0.340 |
Why?
|
| Social Determinants of Health | 3 | 2021 | 101 | 0.340 |
Why?
|
| Papillomavirus Vaccines | 2 | 2022 | 58 | 0.330 |
Why?
|
| Body Mass Index | 8 | 2021 | 773 | 0.330 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 206 | 0.320 |
Why?
|
| Body Weight | 3 | 2023 | 452 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 329 | 0.320 |
Why?
|
| Hemodynamics | 2 | 2023 | 731 | 0.310 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 261 | 0.310 |
Why?
|
| Nutrition Surveys | 3 | 2014 | 111 | 0.300 |
Why?
|
| Blood Glucose | 1 | 2012 | 837 | 0.300 |
Why?
|
| California | 6 | 2016 | 146 | 0.300 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 248 | 0.300 |
Why?
|
| Internship and Residency | 6 | 2023 | 1048 | 0.300 |
Why?
|
| Infant Care | 2 | 2017 | 6 | 0.290 |
Why?
|
| United States | 12 | 2024 | 7003 | 0.290 |
Why?
|
| Vaccination Refusal | 2 | 2017 | 10 | 0.290 |
Why?
|
| Diet Records | 3 | 2017 | 19 | 0.280 |
Why?
|
| Child Development | 2 | 2021 | 167 | 0.280 |
Why?
|
| Metagenome | 3 | 2022 | 105 | 0.280 |
Why?
|
| Obesity | 4 | 2015 | 971 | 0.280 |
Why?
|
| Insulin | 1 | 2012 | 1147 | 0.280 |
Why?
|
| Uganda | 5 | 2024 | 37 | 0.280 |
Why?
|
| Nutrition Assessment | 4 | 2016 | 20 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2023 | 581 | 0.270 |
Why?
|
| Milk, Human | 2 | 2016 | 46 | 0.270 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 599 | 0.260 |
Why?
|
| Education, Medical, Graduate | 3 | 2019 | 395 | 0.260 |
Why?
|
| Colitis, Ulcerative | 2 | 2023 | 739 | 0.260 |
Why?
|
| Exercise Tolerance | 2 | 2023 | 54 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 3667 | 0.260 |
Why?
|
| Reproducibility of Results | 6 | 2023 | 2760 | 0.260 |
Why?
|
| Ileum | 2 | 2024 | 160 | 0.260 |
Why?
|
| Biomarkers | 5 | 2024 | 1769 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1714 | 0.250 |
Why?
|
| Pregnancy | 7 | 2023 | 3024 | 0.250 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 521 | 0.250 |
Why?
|
| Treatment Outcome | 12 | 2024 | 8251 | 0.250 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2024 | 5 | 0.240 |
Why?
|
| Hospitalization | 2 | 2021 | 877 | 0.240 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 3013 | 0.240 |
Why?
|
| Logistic Models | 5 | 2024 | 1213 | 0.240 |
Why?
|
| Vasopressins | 1 | 2024 | 50 | 0.240 |
Why?
|
| Furosemide | 1 | 2024 | 34 | 0.240 |
Why?
|
| Vasoconstrictor Agents | 1 | 2024 | 56 | 0.230 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2024 | 40 | 0.230 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 8 | 0.230 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2024 | 43 | 0.230 |
Why?
|
| Fatty Acids | 2 | 2016 | 134 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2024 | 335 | 0.230 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 66 | 0.230 |
Why?
|
| Renal Replacement Therapy | 4 | 2024 | 34 | 0.230 |
Why?
|
| Cation Transport Proteins | 1 | 2024 | 67 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2017 | 338 | 0.230 |
Why?
|
| Cognition | 2 | 2020 | 579 | 0.230 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2024 | 54 | 0.230 |
Why?
|
| Creatinine | 1 | 2024 | 294 | 0.220 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2024 | 34 | 0.220 |
Why?
|
| Myocarditis | 1 | 2024 | 51 | 0.220 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2024 | 101 | 0.220 |
Why?
|
| Isosorbide Dinitrate | 1 | 2023 | 2 | 0.220 |
Why?
|
| Arterial Switch Operation | 1 | 2023 | 5 | 0.220 |
Why?
|
| Waiting Lists | 1 | 2024 | 184 | 0.220 |
Why?
|
| Pancreatitis | 1 | 2023 | 86 | 0.220 |
Why?
|
| Echocardiography | 4 | 2023 | 937 | 0.220 |
Why?
|
| Transposition of Great Vessels | 1 | 2023 | 24 | 0.220 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2013 | 37 | 0.220 |
Why?
|
| Incidence | 5 | 2021 | 1597 | 0.210 |
Why?
|
| Multiple Organ Failure | 1 | 2023 | 53 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3452 | 0.210 |
Why?
|
| Phenotype | 3 | 2024 | 2445 | 0.210 |
Why?
|
| Fusobacterium nucleatum | 1 | 2022 | 4 | 0.210 |
Why?
|
| Patient Compliance | 2 | 2017 | 231 | 0.210 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2023 | 111 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1072 | 0.210 |
Why?
|
| Ohio | 5 | 2021 | 40 | 0.210 |
Why?
|
| Infant, Premature | 1 | 2024 | 298 | 0.200 |
Why?
|
| Linear Models | 2 | 2014 | 421 | 0.200 |
Why?
|
| Cohort Effect | 1 | 2021 | 5 | 0.200 |
Why?
|
| Biliary Atresia | 1 | 2022 | 22 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 45 | 0.200 |
Why?
|
| Adult Children | 1 | 2021 | 12 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 871 | 0.200 |
Why?
|
| Streptococcal Infections | 1 | 2022 | 56 | 0.200 |
Why?
|
| Hospital Mortality | 1 | 2024 | 387 | 0.200 |
Why?
|
| Poverty | 2 | 2021 | 180 | 0.200 |
Why?
|
| Metagenomics | 1 | 2022 | 91 | 0.200 |
Why?
|
| Cholestasis | 1 | 2022 | 45 | 0.200 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 27 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 742 | 0.200 |
Why?
|
| Bacterial Load | 1 | 2021 | 19 | 0.190 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 132 | 0.190 |
Why?
|
| Survivors | 2 | 2015 | 234 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2023 | 136 | 0.190 |
Why?
|
| Syncope | 1 | 2021 | 34 | 0.190 |
Why?
|
| Mental Recall | 2 | 2015 | 161 | 0.190 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 45 | 0.190 |
Why?
|
| Predictive Value of Tests | 6 | 2023 | 1725 | 0.190 |
Why?
|
| Analysis of Variance | 2 | 2014 | 900 | 0.190 |
Why?
|
| Liver | 2 | 2023 | 1209 | 0.190 |
Why?
|
| Mycobiome | 1 | 2020 | 1 | 0.190 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2020 | 15 | 0.190 |
Why?
|
| Tetralogy of Fallot | 1 | 2021 | 44 | 0.190 |
Why?
|
| Erythropoiesis | 1 | 2021 | 51 | 0.190 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2023 | 192 | 0.180 |
Why?
|
| Tissue Donors | 2 | 2022 | 495 | 0.180 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 26 | 0.180 |
Why?
|
| Decision Making | 2 | 2020 | 667 | 0.180 |
Why?
|
| Thrombophilia | 1 | 2020 | 23 | 0.180 |
Why?
|
| Atrial Function, Left | 1 | 2021 | 50 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 51 | 0.180 |
Why?
|
| Risk Adjustment | 1 | 2020 | 38 | 0.180 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 52 | 0.180 |
Why?
|
| Electric Countershock | 1 | 2021 | 55 | 0.180 |
Why?
|
| Atrial Function | 1 | 2020 | 19 | 0.180 |
Why?
|
| Sepsis | 1 | 2024 | 322 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 68 | 0.180 |
Why?
|
| Blood Gas Analysis | 1 | 2020 | 38 | 0.180 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2023 | 182 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2022 | 211 | 0.180 |
Why?
|
| Electrodes, Implanted | 1 | 2021 | 182 | 0.180 |
Why?
|
| Cardiology | 1 | 2021 | 115 | 0.180 |
Why?
|
| Life Style | 2 | 2011 | 173 | 0.180 |
Why?
|
| Electrocardiography | 2 | 2020 | 496 | 0.180 |
Why?
|
| Bacteria | 2 | 2021 | 478 | 0.180 |
Why?
|
| Environmental Monitoring | 1 | 2020 | 75 | 0.180 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2020 | 98 | 0.180 |
Why?
|
| Primary Prevention | 1 | 2021 | 82 | 0.180 |
Why?
|
| Secondary Prevention | 1 | 2021 | 158 | 0.180 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2020 | 109 | 0.180 |
Why?
|
| Delirium | 1 | 2021 | 71 | 0.180 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2020 | 52 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 200 | 0.170 |
Why?
|
| Air Pollution | 1 | 2021 | 92 | 0.170 |
Why?
|
| Age Factors | 4 | 2021 | 1872 | 0.170 |
Why?
|
| Air Pollution, Indoor | 1 | 2020 | 64 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2021 | 124 | 0.170 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 45 | 0.170 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2019 | 21 | 0.170 |
Why?
|
| Patient Simulation | 1 | 2019 | 42 | 0.170 |
Why?
|
| Transplant Recipients | 1 | 2020 | 137 | 0.170 |
Why?
|
| Carbon Dioxide | 1 | 2020 | 201 | 0.170 |
Why?
|
| Intestinal Mucosa | 1 | 2024 | 805 | 0.170 |
Why?
|
| Wound Healing | 1 | 2021 | 359 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 161 | 0.160 |
Why?
|
| Defibrillators, Implantable | 1 | 2021 | 145 | 0.160 |
Why?
|
| Motor Activity | 2 | 2012 | 327 | 0.160 |
Why?
|
| Colectomy | 1 | 2020 | 172 | 0.160 |
Why?
|
| Influenza Vaccines | 2 | 2017 | 150 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 1843 | 0.160 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2020 | 107 | 0.160 |
Why?
|
| Self Report | 2 | 2017 | 297 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2020 | 280 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2021 | 322 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 217 | 0.160 |
Why?
|
| Formative Feedback | 1 | 2018 | 13 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 6816 | 0.160 |
Why?
|
| Parents | 2 | 2018 | 287 | 0.150 |
Why?
|
| Survival Rate | 4 | 2024 | 1903 | 0.150 |
Why?
|
| Family | 1 | 2020 | 325 | 0.150 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 54 | 0.150 |
Why?
|
| Professional Competence | 1 | 2018 | 69 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 175 | 0.150 |
Why?
|
| Aorta | 1 | 2019 | 288 | 0.150 |
Why?
|
| Thrombosis | 1 | 2020 | 302 | 0.150 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 5 | 0.150 |
Why?
|
| Coronary Vessels | 1 | 2019 | 192 | 0.150 |
Why?
|
| Calcinosis | 1 | 2019 | 230 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 588 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 245 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 144 | 0.150 |
Why?
|
| Books | 1 | 2017 | 4 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2021 | 455 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 496 | 0.140 |
Why?
|
| Pamphlets | 1 | 2017 | 14 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2024 | 2284 | 0.140 |
Why?
|
| Learning | 2 | 2019 | 285 | 0.140 |
Why?
|
| Gene Expression | 1 | 2021 | 1310 | 0.140 |
Why?
|
| Aortic Valve | 1 | 2019 | 244 | 0.140 |
Why?
|
| Preventive Health Services | 1 | 2017 | 39 | 0.140 |
Why?
|
| Sudden Infant Death | 1 | 2017 | 27 | 0.140 |
Why?
|
| Office Visits | 1 | 2017 | 50 | 0.140 |
Why?
|
| Child Health Services | 1 | 2017 | 48 | 0.140 |
Why?
|
| Meat | 2 | 2016 | 27 | 0.140 |
Why?
|
| Risk | 3 | 2017 | 657 | 0.140 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2019 | 275 | 0.140 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 5 | 0.140 |
Why?
|
| Lactation | 1 | 2016 | 54 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 83 | 0.140 |
Why?
|
| Dietary Fats | 3 | 2013 | 135 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2019 | 322 | 0.140 |
Why?
|
| Feces | 3 | 2023 | 331 | 0.140 |
Why?
|
| Trisaccharides | 1 | 2015 | 12 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2017 | 344 | 0.130 |
Why?
|
| Stroke Volume | 3 | 2024 | 463 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 2016 | 70 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 32 | 0.130 |
Why?
|
| Health Promotion | 1 | 2017 | 165 | 0.130 |
Why?
|
| Short Bowel Syndrome | 1 | 2015 | 38 | 0.130 |
Why?
|
| Shellfish | 1 | 2015 | 4 | 0.130 |
Why?
|
| Seafood | 1 | 2015 | 10 | 0.130 |
Why?
|
| Neoplasms | 1 | 2011 | 3043 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 690 | 0.130 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.130 |
Why?
|
| Prognosis | 3 | 2024 | 3788 | 0.130 |
Why?
|
| Internet | 1 | 2017 | 320 | 0.120 |
Why?
|
| SEER Program | 2 | 2013 | 197 | 0.120 |
Why?
|
| Overweight | 1 | 2015 | 119 | 0.120 |
Why?
|
| Adipokines | 1 | 2014 | 17 | 0.120 |
Why?
|
| Dietary Fiber | 2 | 2013 | 44 | 0.120 |
Why?
|
| Tocopherols | 1 | 2013 | 6 | 0.110 |
Why?
|
| Bone Density | 1 | 2015 | 209 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 77 | 0.110 |
Why?
|
| Diet Surveys | 1 | 2013 | 20 | 0.110 |
Why?
|
| Time Factors | 4 | 2024 | 5340 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2664 | 0.110 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 314 | 0.110 |
Why?
|
| Hypertension | 1 | 2019 | 746 | 0.110 |
Why?
|
| Asthma | 1 | 2021 | 977 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2014 | 1534 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 73 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 114 | 0.110 |
Why?
|
| Nebraska | 1 | 2012 | 14 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 29 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 296 | 0.110 |
Why?
|
| Vitamin B 6 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Mutation | 1 | 2024 | 4143 | 0.110 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 61 | 0.100 |
Why?
|
| Intestines | 1 | 2015 | 416 | 0.100 |
Why?
|
| Exercise | 4 | 2021 | 325 | 0.100 |
Why?
|
| Environment Design | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cause of Death | 1 | 2013 | 269 | 0.100 |
Why?
|
| Primary Health Care | 3 | 2021 | 352 | 0.100 |
Why?
|
| Genistein | 1 | 2011 | 16 | 0.100 |
Why?
|
| Abdominal Pain | 2 | 2023 | 138 | 0.100 |
Why?
|
| Lipoproteins, HDL | 2 | 2023 | 97 | 0.100 |
Why?
|
| Nipple Aspirate Fluid | 1 | 2011 | 1 | 0.100 |
Why?
|
| Soybean Proteins | 1 | 2011 | 5 | 0.100 |
Why?
|
| Estrone | 1 | 2011 | 10 | 0.100 |
Why?
|
| Geography | 1 | 2012 | 227 | 0.100 |
Why?
|
| Exercise Test | 2 | 2023 | 166 | 0.090 |
Why?
|
| Cataract | 1 | 2011 | 86 | 0.090 |
Why?
|
| Gestational Age | 2 | 2023 | 329 | 0.090 |
Why?
|
| Dietary Sucrose | 1 | 2010 | 13 | 0.090 |
Why?
|
| Organ Size | 2 | 2022 | 370 | 0.090 |
Why?
|
| Estradiol | 1 | 2011 | 251 | 0.090 |
Why?
|
| Saliva | 2 | 2021 | 124 | 0.090 |
Why?
|
| Inflammation | 3 | 2023 | 971 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 856 | 0.080 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 605 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 323 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 401 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2010 | 222 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2022 | 860 | 0.080 |
Why?
|
| Los Angeles | 3 | 2013 | 28 | 0.080 |
Why?
|
| Kidney | 2 | 2024 | 1147 | 0.080 |
Why?
|
| Animals | 5 | 2024 | 27396 | 0.080 |
Why?
|
| Vaccination | 2 | 2022 | 275 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2017 | 0.070 |
Why?
|
| Mice | 4 | 2024 | 11772 | 0.070 |
Why?
|
| Mass Screening | 2 | 2023 | 637 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2023 | 785 | 0.070 |
Why?
|
| Residence Characteristics | 2 | 2019 | 202 | 0.070 |
Why?
|
| Triglycerides | 2 | 2021 | 232 | 0.070 |
Why?
|
| Cholesterol, HDL | 2 | 2021 | 168 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 2368 | 0.070 |
Why?
|
| Cholesterol | 2 | 2021 | 359 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 1376 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 765 | 0.060 |
Why?
|
| Bumetanide | 1 | 2024 | 4 | 0.060 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2024 | 14 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1553 | 0.060 |
Why?
|
| Lipocalins | 1 | 2024 | 35 | 0.060 |
Why?
|
| Manganese | 1 | 2024 | 55 | 0.060 |
Why?
|
| Blalock-Taussig Procedure | 1 | 2024 | 12 | 0.060 |
Why?
|
| Guanylate Cyclase | 1 | 2023 | 19 | 0.060 |
Why?
|
| Case Management | 1 | 2023 | 25 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 389 | 0.060 |
Why?
|
| Rectum | 1 | 2024 | 148 | 0.060 |
Why?
|
| Venous Pressure | 1 | 2023 | 11 | 0.060 |
Why?
|
| Politics | 1 | 2023 | 52 | 0.060 |
Why?
|
| Catastrophization | 1 | 2023 | 7 | 0.060 |
Why?
|
| Butyrates | 1 | 2023 | 46 | 0.050 |
Why?
|
| Infant Mortality | 1 | 2023 | 59 | 0.050 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2024 | 77 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 47 | 0.050 |
Why?
|
| Dilatation | 1 | 2023 | 48 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2023 | 47 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2344 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2023 | 78 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1177 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2023 | 146 | 0.050 |
Why?
|
| Triage | 1 | 2023 | 111 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 118 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2023 | 146 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2023 | 105 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2415 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 314 | 0.050 |
Why?
|
| Bile Ducts | 1 | 2022 | 59 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2023 | 201 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 168 | 0.050 |
Why?
|
| Vehicle Emissions | 1 | 2021 | 3 | 0.050 |
Why?
|
| Pregnancy in Diabetics | 1 | 2021 | 38 | 0.050 |
Why?
|
| Acute Disease | 1 | 2023 | 841 | 0.050 |
Why?
|
| Anthropometry | 1 | 2021 | 75 | 0.050 |
Why?
|
| Sputum | 1 | 2021 | 35 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 192 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 351 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 149 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 23 | 0.050 |
Why?
|
| Travel | 1 | 2021 | 71 | 0.050 |
Why?
|
| Air Microbiology | 1 | 2020 | 5 | 0.050 |
Why?
|
| Heart Block | 1 | 2020 | 31 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 394 | 0.050 |
Why?
|
| Knowledge | 1 | 2020 | 29 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 217 | 0.050 |
Why?
|
| Social Class | 1 | 2021 | 136 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 326 | 0.050 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 172 | 0.050 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 67 | 0.050 |
Why?
|
| Counseling | 1 | 2022 | 164 | 0.050 |
Why?
|
| DNA, Fungal | 1 | 2020 | 58 | 0.050 |
Why?
|
| Dust | 1 | 2020 | 26 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2020 | 38 | 0.050 |
Why?
|
| Hospitals | 1 | 2023 | 299 | 0.040 |
Why?
|
| Housing | 1 | 2020 | 45 | 0.040 |
Why?
|
| North America | 1 | 2021 | 185 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2020 | 92 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2022 | 524 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 125 | 0.040 |
Why?
|
| Methionine | 1 | 2020 | 65 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2021 | 242 | 0.040 |
Why?
|
| Fungi | 1 | 2020 | 66 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 276 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2021 | 104 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2020 | 119 | 0.040 |
Why?
|
| Respiratory System | 1 | 2020 | 116 | 0.040 |
Why?
|
| Critical Care | 1 | 2023 | 381 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 243 | 0.040 |
Why?
|
| Meglumine | 1 | 2019 | 38 | 0.040 |
Why?
|
| Elastic Tissue | 1 | 2019 | 18 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 264 | 0.040 |
Why?
|
| Placenta | 1 | 2021 | 179 | 0.040 |
Why?
|
| Polysomnography | 1 | 2020 | 151 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 1088 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 506 | 0.040 |
Why?
|
| Autopsy | 1 | 2019 | 122 | 0.040 |
Why?
|
| Heart Atria | 1 | 2021 | 281 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 245 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 293 | 0.040 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 53 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 137 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 780 | 0.040 |
Why?
|
| Poverty Areas | 1 | 2018 | 37 | 0.040 |
Why?
|
| Computers, Handheld | 1 | 2018 | 33 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 782 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 789 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 276 | 0.040 |
Why?
|
| Cell Phone | 1 | 2018 | 38 | 0.040 |
Why?
|
| Lung | 1 | 2024 | 1264 | 0.040 |
Why?
|
| Artifacts | 1 | 2019 | 247 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 689 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 684 | 0.040 |
Why?
|
| Social Work | 1 | 2017 | 20 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 435 | 0.040 |
Why?
|
| Dairy Products | 1 | 2016 | 11 | 0.040 |
Why?
|
| Video Recording | 1 | 2018 | 203 | 0.040 |
Why?
|
| Mexico | 1 | 2016 | 70 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 969 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1243 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 130 | 0.030 |
Why?
|
| Patient Preference | 1 | 2017 | 111 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 28 | 0.030 |
Why?
|
| China | 1 | 2016 | 233 | 0.030 |
Why?
|
| Teaching | 1 | 2017 | 147 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 308 | 0.030 |
Why?
|
| Cecum | 1 | 2015 | 69 | 0.030 |
Why?
|
| Urban Population | 1 | 2017 | 225 | 0.030 |
Why?
|
| Croatia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1185 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 119 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1669 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1489 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 127 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 374 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2014 | 13 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 1092 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 590 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 1069 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2015 | 277 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 922 | 0.030 |
Why?
|
| Xanthophylls | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cryptoxanthins | 1 | 2013 | 2 | 0.030 |
Why?
|
| beta Carotene | 1 | 2013 | 4 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2013 | 30 | 0.030 |
Why?
|
| Vitamin E | 1 | 2013 | 32 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 39 | 0.030 |
Why?
|
| Micronutrients | 1 | 2013 | 18 | 0.030 |
Why?
|
| Australia | 1 | 2013 | 101 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 84 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 119 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2017 | 350 | 0.030 |
Why?
|
| Folic Acid | 1 | 2013 | 63 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 11 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 10 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 458 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 17 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 453 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2012 | 15 | 0.030 |
Why?
|
| Mutagens | 1 | 2012 | 31 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 12 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 48 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 261 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 315 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2012 | 50 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2012 | 38 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 225 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 895 | 0.020 |
Why?
|
| Antioxidants | 1 | 2013 | 226 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 274 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 155 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 57 | 0.020 |
Why?
|
| Heart Failure | 1 | 2020 | 1186 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 171 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 272 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 304 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 195 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 576 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 699 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 988 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 269 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3222 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 839 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1150 | 0.020 |
Why?
|